Combination therapies for chronic hepatitis B in the era of emerging novel drugs.

ABSTRACT:

Background/objectives

Chronic Hepatitis B (CHB) is a global health concern, affecting hundreds of millions and potentially leading to severe outcomes, such as cirrhosis and hepatocellular carcinoma. The primary treatment goal is to achieve a functional cure-defined as the loss of hepatitis B surface antigen (HBsAg) 24 weeks after the cessation of therapy-which reduces liver inflammation, improves histopathology, and decreases the incidence of end-stage liver disease. However, this goal is rarely achieved with current therapies, especially monotherapies. With a deeper understanding of the HBV lifecycle and its interactions with the host immune system, combination therapy strategies are increasingly demonstrating potential to enhance treatment outcomes for CHB.

Methods

This ar

SUBMITTER: Weng D 

PROVIDER: S-EPMC12923412 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature